share_log

Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target

Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target

康泰尔菲茨杰拉克保持对crinetics药业的超重评级,维持90美元的价格目标
Benzinga ·  09/16 11:36  · 评级/大行评级

Cantor Fitzgerald analyst Josh Schimmer reiterates Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and maintains $90 price target.

康特菲芮分析师Josh Schimmer重申Crinetics Pharmaceuticals(纳斯达克:CRNX)的股票评级为“增持”,并维持90美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发